P. A-M retweeted
#Oncología | 🦠 Un virus oncolítico combinado con quimioterapia mejora la supervivencia en #CáncerDePáncreas metastásico.
➡️Estudio internacional liderado por el @H12Octubre 🧬 diariomedico.com/medicina/on…
Nature research paper: NRF2 is a mechanosensitive checkpoint for NLRP3 inflammasome activation
go.nature.com/4jd7JcM
P. A-M retweeted
Super proud to announce AlphaGenome 2 - our new DNA sequence model! 🧬 It predicts the impact of DNA variants in different specific cell types - unlocking crucial information for understanding complex diseases. Available for academic research via our API: alphagenomedocs.com/
P. A-M retweeted
USC Stem Cell won a $6.9 million CIRM grant to finish preclinical work on a heart muscle therapy made from stem cells. The goal is a first human safety trial in late 2027 for people with severe heart attacks (cardiogenic shock), at USC and UW.
stemcell.keck.usc.edu/cirm-a…
P. A-M retweeted
BioCardia $BCDA said today it has finished consultations with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on the application package for its CardiAMP cell therapy system in ischemic heart failure with a target of treating its first Japanese patients in 2028.
stemcelltracker.com/news/car…
The US mid-term elections swept the Democratic party to power in both chambers of the US Congress, raising hopes that lawmakers will now push back against disruptions to science introduced by the Trump administration.
go.nature.com/4iw9Sib
P. A-M retweeted
#Empresas |🧬Syntax Bio logra dirigir células madre hacia estados similares a los de las células beta pancreáticas en solo 4 días mediante CRISPRa.
➡ Un avance prometedor para el desarrollo de terapias celulares frente a la diabetes tipo 1. 🔬 diariomedico.com/medicina/em…
P. A-M retweeted
Top indications for global cancer vaccine trials:
1. Melanoma (263)
2. Lung cancer (216)
3. Breast cancer (176)
Particularly exciting to me are the cancer interception studies (aiming to prevent progression from pre-cancer to cancer) — there are 51 of those, globally.
We mapped the global landscape of cancer vaccine clinical trials.
There are 1689 ongoing programs: 640 in phase 1, 786 in phase 2, and 101 in phase 3.
Most of them are funded by US institutions (601 trials), followed by China (215) and Japan (141).
The top indications are melanoma (263), followed by lung cancer (216) and breast cancer (176).
The most common companion immunotherapy is the PD1 inhibitor, pembrolizumab, but some trials test next-gen immunotherapies, including PD1/VEGF and PDL1/TGF-β bispecifics.
The full analysis is here: breakthrough.elabela.co/p/th…
P. A-M retweeted
Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting
The findings show precise correction of the #SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult #hemoglobin (HbA)
@vbarsan
hubs.li/Q04DgDpy0
P. A-M retweeted
November is American Diabetes Month, a time to raise awareness of the challenges faced by those living with diabetes.
At iTolerance, we're committed to advancing innovative cell therapy approaches that may transform treatment options for Type 1 diabetes.
#T1D #Type1Diabetes
P. A-M retweeted
La Unidad de Producción de Medicamentos de Terapia Avanzada del Hospital La Paz (Madrid) busca Responsable y Técnico de Control de Calidad para su Sala Blanca. Consulta, todos los requisitos y condiciones, y aplica aquí: redteravplus.es/redterav/job…
P. A-M retweeted
Today we announced that initial clinical data from our ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana.
Read more: accessnewswire.com/newsroom/…
#ASH2026
P. A-M retweeted
#Empresas |💊Llega a España el primer agonista del #GLP-1 en pastilla para #obesidad.
👉'Wegovy' oral tiene un perfil de eficacia y seguridad y un precio similar al 💉inyectable. diariomedico.com/farmacia/in…
P. A-M retweeted
RNA Modifications in Cancer Therapy Resistance: Mechanisms and Therapeutic Targeting dlvr.it/TW9rnG #MTNA
P. A-M retweeted
#Empresas |🧬Hito en #inmunoterapia: la FDA aprueba la primera terapia basada en #ADN plasmídico para reducir las cirugías en adultos con papilomatosis respiratoria recurrente.
💉Desarrollada por la estadounidense @InovioPharma, abre una nueva vía frent... diariomedico.com/medicina/em…
P. A-M retweeted
🥼 Scientists conducted a first-in-human #ClinicalTrial involving a single intravenous infusion of glycocalyx-edited autologous bone marrow-derived mesenchymal stem cells in ten women with advanced-stage #osteoporosis.
🔎 Read more in @CellCellPress: bit.ly/4iVknvZ.
P. A-M retweeted
#Empresas |🧬La FDA amplía talazoparib + enzalutamida en cáncer de próstata metastásico hormonosensible con mutaciones HRR.
➡La combinación de @pfizer reduce un 52% el riesgo de progresión o muerte.💊 diariomedico.com/medicina/em…
P. A-M retweeted
In medicine we say “recommendations as per our prior notes; thank you for this interesting consult, signing off”
This Post is from a suspended account. Learn more
P. A-M retweeted
🤝Los oncólogos en Europa (@myESMO) y EEUU (@ASCO) se alían para ❌reducir la 📃burocracia de los 🧪ensayos clínicos.
👉Estiman que los investigadores recogen entre 10 y 20 veces más información de la necesaria.
diariomedico.com/medicina/on…
P. A-M retweeted
📢Nuevos resultados de fase III muestran una alta eficacia de 💉tezepelumab, de @AstraZeneca y @Amgen, en esofagitis eosinofílica 👇.
diariomedico.com/medicina/al…



















